Welcome to our dedicated page for Mirion Technologies news (Ticker: MIR), a resource for investors and traders seeking the latest updates and insights on Mirion Technologies stock.
Mirion Technologies Inc (MIR) delivers critical radiation safety solutions for nuclear energy, healthcare, and global security markets. This news hub provides investors and industry professionals with essential updates on the company developments shaping radiation detection technologies.
Access timely reports covering earnings announcements, product innovations, strategic partnerships, and regulatory milestones. Our curated collection features press releases and analysis on Mirion's Nuclear & Safety segment advancements and Medical division breakthroughs in cancer treatment safety.
Key updates include radiation monitoring system launches, international expansion efforts, and R&D initiatives addressing emerging nuclear safety challenges. Bookmark this page for structured access to operational updates from Mirion's global facilities and executive leadership commentary.
For stakeholders tracking radiation protection technologies, this resource offers comprehensive monitoring of Mirion's progress in dosimetry systems, environmental monitoring solutions, and medical radiation processing advancements. Return regularly for verified updates maintaining compliance with financial disclosure standards.
Mirion Technologies reported strong Q1 2025 financial results, with revenues increasing 4.9% to $202.0 million. The company achieved a significant turnaround, posting a GAAP net income of $0.4 million compared to a $26.5 million loss in Q1 2024.
Key highlights include:
- Adjusted EBITDA rose 18% to $46.7 million
- Adjusted earnings per share improved to $0.10 from $0.06
- Total orders increased 11.5% to $203 million
The company updated its 2025 guidance, projecting revenue growth of 5.0-7.0% and organic revenue growth of 5.5-7.5%. Despite new tariff impacts and U.S. government funding reductions, Mirion reaffirmed its Adjusted EBITDA target of $215-230 million and Adjusted EPS guidance of $0.45-$0.50 per share.
Mirion Technologies (NYSE: MIR) has scheduled its first quarter 2025 financial results release for Tuesday, April 29, 2025, after market close. The company will host a conference call on Wednesday, April 30, 2025, at 11:00 am ET to discuss the quarterly performance.
Investors can join the earnings call by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international). A live webcast will be available on the company's investor relations website. A replay of the call will be accessible until May 14, 2025, via phone using access code 13753466 or through Mirion's IR website.
Mirion Technologies (NYSE: MIR) has launched version 1.2 of its Apex-Guard gamma spectroscopy software, enhancing quality control in radiopharmaceutical production. The updated software introduces a patent-pending algorithm for Radionuclidic purity measurements, supporting compliance with FDA regulations.
The release comes amid rapid expansion in the radiopharmaceutical sector, with over 100 drugs in Phase I or further clinical development. The software builds upon Mirion's Genie™ and Apex-Gamma™ platforms, offering advanced controls, security, and audit features. It integrates with BioTrax QMS®, an electronic quality management system from ec2 Software, a Mirion Medical Company.
This enhancement aims to streamline quality management processes and ensure compliance in radioisotope production, particularly important for cancer care applications.
Mirion Technologies (NYSE: MIR) has secured contracts to provide critical systems for TerraPower's Natrium Reactor Demonstration Project in Wyoming, the first commercial advanced nuclear power plant in the U.S. The project, a public-private partnership between TerraPower and the U.S. Department of Energy, will implement Natrium technology combining a sodium-cooled fast reactor with molten salt energy storage.
Mirion will deliver two key systems:
- Radiation Monitoring System (RMS) featuring area, effluent, and process radiation monitors for continuous plant safety monitoring
- Nuclear Instrumentation System (XIS) for detecting reactor power levels
The contracts position Mirion to support innovative nuclear technologies, including small and advanced modular reactors, contributing to meeting modern energy demands with safe, sustainable nuclear power.
Mirion Technologies (NYSE: MIR), a leading provider of advanced radiation safety solutions, has announced its membership in two major nuclear industry organizations. The company has joined the Nuclear Energy Institute (NEI) and enhanced its partnership with the American Nuclear Society (ANS) as a Trustees of Nuclear partner.
Through NEI membership, Mirion will participate in policy discussions shaping the nuclear industry and advocate for nuclear energy growth policies. As an ANS Trustee of Nuclear, the company will serve on its leadership council. CEO Thomas Logan emphasized Mirion's unique position across the nuclear landscape and its commitment to advancing the industry through these strategic partnerships.
Mirion Technologies (NYSE: MIR) has announced its participation in the 46th Annual Raymond James Institutional Investor Conference. The company's leadership team, including CEO Thomas Logan and CFO Brian Schopfer, will deliver a presentation scheduled for Wednesday, March 5, 2025, at 9:15 a.m. ET.
The presentation will be accessible through a live webcast on Mirion's Investor Relations Page under the 'Events and Presentations' section. An archived version of the webcast will also be made available at the same location for those unable to attend the live session.
Mirion Technologies (NYSE: MIR) has announced its participation in Citi's 2025 Global Industrial Tech and Mobility Conference in Miami, FL. The company's leadership, including CEO Thomas Logan and CFO Brian Schopfer, will deliver a presentation scheduled for Wednesday, February 19, 2025, at 2:40 PM ET.
Investors and interested parties can access the live webcast through Mirion's Investor Relations Page under the 'Events and Presentations' section. An archived version of the presentation will also be made available at the same location for those unable to attend the live event.
Mirion (NYSE: MIR) reported strong financial results for Q4 and full year 2024, with significant improvements across key metrics. Q4 revenues increased 10.4% to $254.3 million, while GAAP net income reached $15.9 million, marking a 210% improvement from the previous year's loss. The company achieved $69.6 million in Adjusted EBITDA, up 14.1% year-over-year.
For 2025, Mirion reaffirmed its guidance, projecting total revenue growth of 4.0-6.0% and organic revenue growth of 5.5-7.5%. The company expects Adjusted EBITDA between $215-230 million and introduced Adjusted EPS guidance of $0.45-0.50 per share. Notably, Mirion entered 2025 with approximately half of expected revenue already in backlog and is advancing discussions on $300-400 million in potential large orders.
Mirion Technologies (NYSE: MIR) has announced its schedule for the release of fourth quarter and full year 2024 financial results. The company will publish its results after market close on Tuesday, February 11, 2025, followed by a conference call on Wednesday, February 12, 2025, at 11:00 am ET.
Investors and interested parties can access the earnings call by dialing 1-877-407-9208 (US) or 1-201-493-6784 (International). A live webcast will be available on the company's investor relations website. A replay of the call will be accessible until February 26, 2025, using access code 13751221, and will also be archived on Mirion's investor website.
Mirion Technologies (NYSE: MIR) is hosting an Investor Day at the New York Stock Exchange to present its updated strategic and financial outlook. The company projects revenue of $1.1 billion by 2028, with 6-8% organic revenue growth, and targets an adjusted EBITDA margin of 30%. For 2025, Mirion forecasts organic revenue growth of 5.5-7.5% and adjusted EBITDA of $215-230 million. The company highlights its position in nuclear power and cancer care markets, announcing an anti-dilutive share repurchase program and updated capital allocation strategy. Management will discuss market opportunities in nuclear power growth, cancer care dynamics, and operational excellence initiatives.
FAQ
What is the current stock price of Mirion Technologies (MIR)?
What is the market cap of Mirion Technologies (MIR)?
